Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

Author(s):
Wortman, B.G.; Creutzberg, C.L. (0000-0002-7008-4321); Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Triest, B. van; Nijman, H.W.; Stelloo, E.; Bosse, T.; Boer, S.M. de; Putten, W.L.J. van; Smit, V.T.H.B.M. (0000-0003-3730-5652); Nout, R.A.; PORTEC Study Grp
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-10-30
Language
English
Is part of
British Journal of Cancer (2018), Vol. 119, no. 9, p. 1067-1074
hdl
1887/86376
doi
10.1038/s41416-018-0310-8